We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-4.85%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.16B
AUM Growth
-$97.2M
Cap. Flow
+$7.64M
Cap. Flow %
0.66%
Top 10 Hldgs %
55.45%
Holding
63
New
12
Increased
17
Reduced
17
Closed
13

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$27.1M
2
PEN icon
Penumbra
PEN
+$24.6M
3
ESRX
Express Scripts Holding Company
ESRX
+$24.3M
4
XNCR icon
Xencor
XNCR
+$24M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$20.5M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$39.3M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$23.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$21.6M
4
ELGX
Endologix Inc
ELGX
+$20.8M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$20.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.86%
2 Miscellaneous 1.19%
3 Financials 0.92%
4 Communication Services 0.62%
5 Consumer Staples 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$146M 12.59%
16,618,776
-39,296
-0.2% -$289K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$80.3M 6.92%
1,520,904
-260,566
-15% -$15.7M
CLVS
3
DELISTED
Clovis Oncology, Inc.
CLVS
$72M 6.2%
1,620,355
-429,630
-21% -$15.1M
PEN icon
4
Penumbra
PEN
$12.7B
$66.4M 5.72%
1,040,208
+367,290
+55% +$24.6M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$61.3M 5.28%
12,331,130
-420,406
-3% -$2.91M
ARIA
6
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$47.7M 4.12%
3,838,376
+1,699,905
+79% +$20.5M
INCY icon
7
Incyte
INCY
$25.2B
$45.3M 3.91%
451,987
-145,651
-24% -$14.2M
MOH icon
8
Molina Healthcare
MOH
$10.4B
$43.7M 3.77%
805,546
+27,386
+4% +$1.5M
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$40.9M 3.53%
366,068
-179,854
-33% -$21.6M
PBYI icon
10
Puma Biotechnology
PBYI
$468M
$39.6M 3.41%
1,290,140
+627,854
+95% +$27.1M
ATRA icon
11
Atara Biotherapeutics
ATRA
$92.3M
$37.9M 3.27%
106,838
+25,973
+32% +$11M
NDRM
12
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$34.6M 2.99%
1,560,819
+755,573
+94% +$14.1M
PRTA icon
13
Prothena Corp
PRTA
$479M
$32.2M 2.77%
653,725
-47,934
-7% -$2.64M
AGIO icon
14
Agios Pharmaceuticals
AGIO
$1.99B
$30.8M 2.66%
738,451
+551
+0.1% +$28.9K
CNC icon
15
Centene
CNC
$32B
$29.2M 2.52%
1,033,196
+105,042
+11% +$3.1M
XNCR icon
16
Xencor
XNCR
$1.94B
$26.2M 2.26%
+996,100
New +$24M
OXFD
17
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$25.4M 2.19%
1,701,049
+269,930
+19% +$3.79M
WVE icon
18
Wave Life Sciences
WVE
$993M
$24.9M 2.15%
951,712
+249,890
+36% +$8.13M
ESRX
19
DELISTED
Express Scripts Holding Company
ESRX
$23.3M 2.01%
+338,800
New +$24.3M
NSTG
20
DELISTED
NanoString Technologies, Inc.
NSTG
$20.9M 1.8%
937,957
-299,478
-24% -$6.42M
ALDR
21
DELISTED
Alder Biopharmaceuticals
ALDR
$19.1M 1.65%
920,550
+218,011
+31% +$5.67M
NVRO
22
DELISTED
NEVRO CORP.
NVRO
$18.9M 1.63%
260,380
+33,113
+15% +$2.83M
CRL icon
23
Charles River Laboratories
CRL
$13.9B
$18.8M 1.62%
247,107
+120,001
+94% +$9.11M
CMRX
24
DELISTED
Chimerix, Inc.
CMRX
$15.4M 1.33%
3,345,959
+131,013
+4% +$619K
BOLD
25
DELISTED
Audentes Therapeutics, Inc
BOLD
$15.2M 1.31%
832,736
-83,890
-9% -$1.45M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2016 Portfolio in Review

As of Q4 2016, Redmile Group held 63 positions worth $1.16B, down 7.7% from $1.26B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group's Q4 2016 filing shows 12 new, 17 increased, 17 reduced and 13 closed positions. Its largest new stake was Express Scripts Holding Company: 338,800 shares worth $23.3M. The largest sale was Sarepta Therapeutics, an estimated $39.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q4 2016 buy was Express Scripts Holding Company: 338,800 shares worth $23.3M.
  • Redmile Group added most to Puma Biotechnology in Q4 2016, an estimated $27.1M increase.
  • Redmile Group's biggest Q4 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $21.6M.
  • Redmile Group fully exited Sarepta Therapeutics in Q4 2016, selling an estimated $39.3M.
  • Redmile Group's ten largest holdings make up 55% of its $1.16B portfolio in Q4 2016.
  • Redmile Group opened 12 new positions and closed 13 in Q4 2016.
  • Redmile Group's portfolio value fell 7.7% quarter-over-quarter to $1.16B.

Based on Redmile Group's 13F filing for Q4 2016, filed 14 Feb 2017.